Caroline Seymour - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Caroline Seymour's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Caroline Seymour
Verified
Managing Editor, OncLive
Cranbury
Beats
Arts and CultureCovers: News
Tech, business
Content
By Caroline Seymour Verified| OncLive Verified Disparate trends in the amount and phase of sarcoma clinical trials, as well as their sponsorship sources, were found in a global analysis presented during the 2025 ESMO Sarcoma and Rare Cancers Congress.1“This idea came to me when I was in Milan a few months ago. When we were going through the clinical trials that were available on site, I saw that despite sarcomas being rare, there were quite a few trials available on site.
By Caroline Seymour Verified| OncLive Verified Disparate trends in the amount and phase of sarcoma clinical trials, as well as their sponsorship sources, were found in a global analysis presented during the 2025 ESMO Sarcoma and Rare Cancers Congress.1“This idea came to me when I was in Milan a few months ago. When we were going through the clinical trials that were available on site, I saw that despite sarcomas being rare, there were quite a few trials available on site.
By Caroline Seymour Verified| OncLive Verified Health Canada has granted a notice of compliance for durvalumab (Imfinzi) as monotherapy for the treatment of patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based chemoradiation therapy.1 The approval was based on findings from the phase 3 ADRIATIC trial, which were first presented at the 2024 ASCO Annual Meeting and subsequently published in the New England Journal of Medicine.2,3 In the trial durvalumab led to a median...
Company Info
OncLive
NeurologyLive is a multimedia platform focused on delivering the latest news and insights in the field of neurology. It serves as a valuable resource for healthcare professionals, particularly those treating neurological diseases. The platform offers a combination of print and digital media, ensuring that busy clinicians stay informed about significant developments in neurology. The services provided by NeurologyLive include breaking news on drug approvals, clinical trials, and emerging trends in neurological care. It features expert interviews with leading neurologists, offering insights into the latest research and clinical practices. The use of multimedia content makes the information accessible and engaging for its audience. NeurologyLive targets healthcare professionals such as neurologists, clinicians, and researchers. It has established strategic partnerships with organizations like the Consortium of Multiple Sclerosis Centers, enhancing its credibility and reach within the neurology community. Its comprehensive coverage and expert engagement position NeurologyLive as a trusted source for the latest developments in the field.
Cranbury, United States
+1 609-716-7777
Founded: 2018